clinical trial · NCT00762645
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Alcon Research·phase4·completed·n = 30
Angle-closure GlaucomaTravoprost 0.004% (Travatan)Pilocarpine 1%
brief summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).
started
Feb 1, 2007
primary completion
May 1, 2008
completion
May 1, 2008
last updated
Dec 6, 2023
official title
A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol